Vaccine against one of the most severe forms of cancer – brain tumors – the first stage of clinical trials in Germany passed. This is reported by Medical Press.
Drug is created from a variable IDH1 protein, which synthesizes tricarboxylic acids. The gene occurs in a mutation that blocks IDH1. Such deviations were detected in 75% of glioma patients. It is this mutation that provokes the development of cancer cells in the brain.
The immune system can recognize the mutant IDH1 protein as a foreign and run the specific response of T-helpers belonging to T-lymphocytes, “experts explain.
Glioma vaccine created several years ago. It was experienced on experimental rats and proved that it is able to stop the growth of cancer cells in which the process of mutation passes. Now it was tested by 32 patients with glioma. Experiment participants passed the entire vaccination rate consisting of eight vaccinations. Heavy side effects were not recorded, but at the same time some patients suffered from an increase in tumor.
“In patients with activated immune cells have successfully penetrated and actively worked in tumor tissue. In 82% of patients with a specific immune response to vaccination, the tumor did not progress for three years,” scientists explain.